Zelma C Chiesa Fuxench, MD

Assistant Professor of Dermatology at the Hospital of the University of Pennsylvania
Department: Dermatology
Contact information
Department of Dermatology
University of Pennsylvania Perelman School of Medicine
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
7th Floor, South Tower
Office #726
Philadelphia, PA 19104
University of Pennsylvania Perelman School of Medicine
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
7th Floor, South Tower
Office #726
Philadelphia, PA 19104
Office: 215-349-5557
Fax: 215-615-3127
Fax: 215-615-3127
Education:
B.S.
University of Puerto Rico (Biology) Magna cum Laude, 2004.
M.D.
University of Puerto Rico School of Medicine Magna cum Laude, 2008.
M.S.C.E
University of Pennsylvania Perelman School of Medicine, 2015.
Permanent linkB.S.
University of Puerto Rico (Biology) Magna cum Laude, 2004.
M.D.
University of Puerto Rico School of Medicine Magna cum Laude, 2008.
M.S.C.E
University of Pennsylvania Perelman School of Medicine, 2015.
Description of Clinical Expertise
General Medical DermatologyAtopic Dermatitis
Psoriasis
Hidradenitis
Description of Research Expertise
Atopic Dermatitis, comorbidities in Atopic Dermatitis, Psoriasis, EpidemiologySelected Publications
Silverberg JI, Chiesa-Fuxench Z, Margolis D, Boguniewicz M, Fonacier L, Grayson M, Simpson E, Ong P: Epidemiology and Burden of Sleep Disturbances in Atopic Dermatitis in US Adults. Dermatitis 01(33): S104-S113, Nov-Dec 2022.Simpson E, Armstrong A, Boguniewicz M, Chiesa Fuxench ZC, Feely M, Pierce E, Sun L, Chen YF, Angle R, Silverberg JI: Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes. Dermatol Ther. Page: e15954. Oct 2022.
Munayco Maldonado, G.M., BA; Foy, V.M., BA; Chiesa Fuxench, Z.C., MD, MSCE: Epidemiology and Clinical Presentation of Pediatric-onset vs. Adult-onset Atopic Dermatitis. 4th Annual Revolutionizing Atopic Dermatitis Conference April 2022.
Michelen-Gomez E, Chiesa Fuxench Zelma C.: The Risk of Herpetic and Non-Herpetic Cutaneous Infections in Adult Patients with Atopic Dermatitis treated with oral Janus Kinase Inhibitors: a systematic review and meta-estimate of randomized clinical trial data. 4th Annual Revolutionizing Atopic Dermatitis Conference April 2022.
Foy VM, BA, Munayco Maldonado G, BA, Chiesa Fuxench ZC, MD MSCE: Atopic Dermatitis in Adults: Experience of a tertiary care center. 4th Annual Revolutionizing Atopic Dermatitis Conference April 2022.
Simpson EL, Silverberg JI, Armstrong AW, Chiesa Fuxench ZC, et al. : Effects of Ruxolitinib Cream on Patient-Reported Quality of Life in Atopic Dermatitis: 52-Week Pooled Results from Two Phase 3 Studies. 4th Annual Revolutionizing Atopic Dermatitis Conference April 2022.
Taylor SC, Alexis AF, Armstrong AW, Chiesa Fuxench ZC, Lim HW: Misconceptions of photoprotection in skin of color. J Am Acad Dermatol 86(3S): S9-S17, March 2022.
Eichenfield LF, Stein Gold, LF, Chiesa Fuxench ZC, Venturanza, ME, et al. : Safety and efficacy over 8 weeks and disease control over 52 weeks with ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from two phase 3 studies. American Academy of Dermatology Annual Meeting March 2022.
Rigel DS, Taylor SC, Lim HW, Alexis AF, Armstrong AW, Chiesa Fuxench ZC, Draelos ZD, Hamzavi IH.: Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel. J Am Acad Dermatol 86(3S): S1-S8, March 2022.
Takeshita J, Gupta J, Zhu Y, Berna R, Chiesa Fuxench ZC, Margolis DJ.: Atopic dermatitis and the atopic march: considering racial and ethnic diversity in atopic disease progression. J Allergy Clin Immunol March 2022.